Attention AACR Annual Meeting 2017 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Cyclin-dependent Kinase and PARP Inhibitor Clinical Trials

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease
Hope S Rugo
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
Fabrice Andre
Institut Gustave Roussy, Université Paris-Sud, Villejuif, France
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Discussant
Filipa Lynce
Georgetown University, Washington, DC, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with RAS mutant solid tumors
Geoffrey I. Shapiro
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
Geoffrey I. Shapiro
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Discussant
Timothy A. Yap
Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy
Anna F Farago
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
Discussant
Caroline Dive
Cancer Research UK Manchester Inst., Manchester, United Kingdom
from AACR Annual Meeting 2017 on April 3, 2017 10:30 AM-12:45 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8